Randomized Study Of CP-675,206 or Best Supportive Care Immediately After Platinum-Based Therapy For Non-Small Cell Lung Cancer (NSCLC)
Public ClinicalTrials.gov record NCT00312975. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2 Randomized, Non-Comparative Study Of CP-675,206 Or Best Supportive Care Immediately Following First-Line, Platinum-Based Therapy In Patients With Stage IIIB (With Effusion) Or Stage IV Non-Small Cell Lung Cancer That Has Responded Or Remained Stable
Study identification
- NCT ID
- NCT00312975
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 90 participants
Conditions and interventions
Conditions
Interventions
- CP-675,206 Drug
- best supportive care Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2006
- Primary completion
- Mar 31, 2008
- Completion
- Jan 31, 2010
- Last update posted
- Jun 6, 2012
2006 – 2010
United States locations
- U.S. sites
- 14
- U.S. states
- 9
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Bentonville | Arkansas | 72712 | — |
| Research Site | Fayetteville | Arkansas | 72703 | — |
| Research Site | Orange | California | 92868 | — |
| Research Site | Danbury | Connecticut | 06810 | — |
| Research Site | Atlanta | Georgia | 30309 | — |
| Research Site | Lexington | Kentucky | 40536-0098 | — |
| Research Site | Alexandria | Louisiana | 71301 | — |
| Research Site | New York | New York | 10032 | — |
| Research Site | Oneida | New York | 13421 | — |
| Research Site | Oswego | New York | 13126 | — |
| Research Site | Syracuse | New York | 13202 | — |
| Research Site | Syracuse | New York | 13210-2306 | — |
| Research Site | Canton | Ohio | 44718 | — |
| Research Site | Philadelphia | Pennsylvania | 19111 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00312975, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 6, 2012 · Synced May 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00312975 live on ClinicalTrials.gov.